Could Amgen’s Patent Victory Be Bad For Medicine?
From the article:
Last night, in a nearly unprecedented move, a federal judge ordered a cholesterol medicine that is on the market and used by patients to be withdrawn because it infringes on the patents of a competitor. Some patent attorneys reacted with shock. (Read the ruling.)
“It’s very strange for a judge to take one product off the market when there are patients on the medicine already,” says Rachel Sachs, an associate professor of law at Washington University in St. Louis. In an extended thread on Twitter about the decision, New York Law School Associate Professor Jacob Sherkow wrote: “I am shocked.”
Read the full article.innovation intellectual property pharmaceuticals rachel sachs regulation